Special Issue "New Insights into Gut Hormones and Intestinal Diseases"
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 3304
It has been evident for some years now that the intestinotrophic hormone glucagon-like peptide-2 (GLP-2) secreted from the entero-endocrine L cells, has therapeutic potential in treating intestinal diseases. Indeed, the GLP-2 analogue teduglutide is available for the treatment of short bowel syndrome. However, in recent years, it has been recognized that this is probably not the only hormone secreted from the gut implicated in either the pathogenesis or the adaptive and regenerating response in the intestines.
The anti-diabetic hormone glucagon-like peptide-1 (GLP-1) has been suggested both as a biomarker of intestinal damage and as a potential drug for the treatment of acute intestinal damage.
In this Special Issue, we wish to focus on all new aspects of the topic of gut hormones and intestinal diseases. Intestinal diseases in this setting include a wide range of conditions, such as short bowel syndrome, inflammatory bowel diseases, cancer, inherited diseases, and intestinal toxicities from other treatments. Suggested topics could be how intestinal disease influences the secretion of gut hormones; if and how these hormones contribute to the pathophysiology, and if the manipulation of gut hormone secretion modifies disease control.
Dr. Hannelouise Kissow
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- short bowel syndrome
- inflammatory bowel disease